What’s the current market cap for Zoetis stock?

Zoetis (ZTS) has a market cap of $33bn as of June 21, 2026.

What is the P/E ratio for Zoetis stock?

The price to earnings (P/E) ratio for Zoetis (ZTS) stock is 12.89 as of June 21, 2026.

Does Zoetis stock pay dividends?

Yes, the Zoetis (ZTS) stock pays dividends to shareholders. As of June 21, 2026, the dividend rate is $2.06 and the yield is 2.69%. Zoetis has a payout ratio of 33.27% on a trailing twelve-month basis.

When is the next Zoetis dividend payment date?

The next Zoetis (ZTS) dividend payment is scheduled for September 01, 2026.

What is the beta indicator for Zoetis?

Zoetis (ZTS) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Zoetis stock | $ZTS Share Price

About Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Ticker

$ZTS

Sector

Health

Primary listing

NYSE

Employees

14,500

Headquarters

Parsippany, United States

Website

www.zoetis.com

Zoetis Metrics

BasicAdvanced

$33bn

12.89

$6.11

0.86

$2.06

2.69%

What the Analysts think about Zoetis

Analyst ratings (Buy, Hold, Sell) for Zoetis stock.

Bulls say / Bears say

Robust international and livestock segment growth, with international revenue up 17% (10% organic) and livestock revenue growing 15% year-over-year, reflecting strong end-market conditions and production animal demand internationally. (Reuters)

Updated full-year 2026 guidance to revenue of $9.68 billion–$9.96 billion and adjusted diluted EPS of $6.85–$7.00, representing organic operational revenue growth of 2%–5% and net income growth of 2%–6%, underscoring management’s confidence in near-term growth. (Reuters)

Definitive agreement to acquire Neogen’s animal genomics business for $160 million, expected to close in H2 2026, bolstering Zoetis’s precision animal health capabilities. (Reuters)

Organic operational revenue was flat in Q1 2026, while U.S. companion animal sales declined 11%, highlighting persistent weakness in its largest market. (Reuters)

U.S. revenue declined 8% to $1.09 billion due to softer companion animal demand and competitive pressure, underscoring vulnerabilities in the domestic business. (Reuters)

Q1 2026 earnings lagged analyst estimates, prompting a view cut and contributing to near-term stock pressure. (Yahoo Finance)

Data summarised monthly by Lightyear AI. Last updated on 19 Jun 2026.

Zoetis Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Zoetis Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Zoetis News

AllArticlesVideos

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

Newsfile Corp·3 days ago

ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

Newsfile Corp·4 days ago

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Newsfile Corp·4 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.